Phosphatidylserine-Targeting Peptoids for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cancer treatments face challenges due to the heterogeneity of protein target expressions in cancer cells, leading to limited effectiveness and significant side effects, as most targeted drugs only act on a small percentage of patients and rely on prior knowledge of protein biomolecules.
Innovation Solution
Development of phosphatidylserine-targeting peptoids, such as 2P3H-PPS1 and 2-4-PPS1, which are administered alone or in combination with docetaxel, to selectively target cancer cells by exploiting the universal expression of phosphatidylserine in the tumor microenvironment, bypassing the need for prior knowledge of specific biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional targeted drugs targeting protein biomolecules are used, then they can address patient-specific molecular defects, but their effectiveness is limited due to high heterogeneity of protein expression in cancer cells
Solution Approach 1:
The patent changes the target parameter from protein biomarkers to lipid biomarkers (phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphotidylglycerol). These lipids are globally expressed in the tumor microenvironment across different cancer types, providing a more universal target that maintains reliability while improving adaptability to diverse patient populations
Solution Approach 2:
The peptoid molecules are designed to target lipid biomarkers that are universally present in cancer cell membranes regardless of cancer type or patient genetics. This universal targeting approach allows a single therapeutic agent to be effective across multiple cancer types and patient populations, improving versatility while maintaining reliability through consistent lipid expression patterns
2Reliability
If approved cancer drugs are used, then they can treat cancer in selected patient groups, but they have considerable side effects and high prices
Solution Approach 1:
The peptoid molecules are designed with specific chemical structures that confer selective affinity for cancer cell membrane lipids versus normal cell lipids. This local quality differentiation allows the drug to concentrate its therapeutic effect specifically at the cancer cell target site while sparing normal tissues, thereby improving effectiveness while reducing side effects
Solution Approach 2:
The patent uses lipid biomarkers in the tumor microenvironment as intermediary targets. These lipids serve as mediators that the peptoid molecules bind to for therapeutic effect. By targeting these intermediary lipid structures rather than directly attacking cancer cells or using conventional chemotherapy agents, the treatment achieves cancer-specific efficacy with reduced harm to normal cells
3Measurement precision
If conventional drug development approaches are used, then they can target specific protein biomarkers, but they depend on prior knowledge of biological roles which limits discovery of novel targets
Solution Approach 1:
Instead of starting with known protein biomarkers and their biological roles (conventional approach), the patent inverts the approach by directly identifying and targeting lipid biomarkers in the tumor microenvironment. This inversion allows discovery of novel therapeutic targets (lipids rather than proteins) without being constrained by prior knowledge of protein function, thereby expanding target discovery capability while maintaining target specificity through the unique lipid targeting mechanism
Data Source
AI summary
A phosphatidylserine targeted peptoid has been identified with the ability to bind to cancer cells globally and specifically. A dimer of the peptoid decreases cancer cell viability. Use of the dimerized peptoid enhances the efficacy of docetaxel. The peptoid can be used for including but not limited to diagnosing and treating cancer, diagnosing and treating a viral condition, and diagnosing and treating diabetes.